mSMART Guidelines for CAR-T Associated Cytokine Release Syndrome
Learn about the mSMART guidelines for the management of CAR-T associated cytokine release syndrome, neurotoxicity, and cytopenias. Find out more about CAR-T associated CRS, neurotoxicity, late neurotoxicity, and post CAR-T cytopenias.
Vincent Rajkumar
Editor-in-Chief, Blood Cancer Journal; Professor, Mayo Clinic; Opinions are solely my personal views; @CovidThreads; https://t.co/HOGYJSpsoG
-
mSMART guidelines for management of CAR-T associated cytokine release syndrome, neurotoxicity, cytopenias has just been posted. #myeloma #MedTwitter @YiLinMDPhD @myelomaMD @MorieGertz @MayoMyeloma https://t.co/pwue1T042G
— Vincent Rajkumar (@VincentRK) June 2, 2023 -
CAR-T associated CRS #ASCO23 pic.twitter.com/sr9tGz9V3g
— Vincent Rajkumar (@VincentRK) June 2, 2023 -
CAR-T associated neurotoxicity #ASCO23 pic.twitter.com/fJJOBzXy54
— Vincent Rajkumar (@VincentRK) June 2, 2023 -
CAR-T associated late neurotoxicity #ASCO23 pic.twitter.com/XVYfguSUQ8
— Vincent Rajkumar (@VincentRK) June 2, 2023 -
Post CAR-T cytopenias pic.twitter.com/aRgJOnnG7m
— Vincent Rajkumar (@VincentRK) June 2, 2023 -
Thanks to @YiLinMDPhD for spearheading our CAR-T and immunotherapy program @MayoClinic @MayoCancerCare and leading the development of these guidelines. @Rfonsi1 @MorieGertz @myelomaMD
— Vincent Rajkumar (@VincentRK) June 2, 2023